Brightsurf Science News & Current Events

June 05, 2010
'2 dogs 2,000 miles' trek promotes dog DNA for cancer research
A man and his two dogs on a 2,000-mile walk to raise awareness about cancer in dogs is helping a new $5.3 million canine cancer project recently launched by the Translational Genomics Research Institute and the Van Andel Research Institute.

US dental schools leave graduates unprepared to screen for sleep disorders
According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the majority of US dental schools have not adequately prepared their graduates to screen for sleep disorders, which affect more than 70 million adults in the US.

Nasendoscopy proves useful in predicting treatment success in sleep apnea patients
Japan-based research shows that nasendoscopy may help dentists predict oral appliance therapy success in sleep apnea patients.

New treatment method safe, effective for advanced melanoma patients
Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly to the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F.

OHSU Emergency Department reports fewer meth-related visits following 2006 'anti-meth' legislation
The number of methamphetamine-related emergency room visits decreased significantly in the year following the implementation of Oregon's law prohibiting the sale of over-the-counter decongestant containing pseudoephedrine, according to Oregon Health & Science Emergency Department physician-researchers.

Sleep apnea patients using oral appliance therapy show high efficacy and compliance
According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, between 31 and 53 months after beginning oral appliance therapy, the sleep apnea treatment remained effective.

Successful Phase III clinical trial results reported for Novocure's novel medical device for treatment of recurrent glioblastoma
Data from the first Phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology Annual Meeting in Chicago.

Neuralstem ALS trial principal investigator to speak at Brookings Institution
Neuralstem Inc., stem cell ALS trial Principal Investigator, Dr. Eva Feldman, will speak at the Brookings Institution on academia and US innovation, citing the trial as an example.

Selenium shows no benefit in prevention of lung cancer
Selenium, a supplement taken daily by millions in hopes of protection against cancer and a host of other diseases, has proven to be of no benefit in reducing a patient's risk of developing lung cancer -- either a recurrence or second primary malignancy, according to results of an international Phase III clinical trial.

Combination treatment regimen not effective against advanced melanoma
The combination of two different chemotherapies and a molecular inhibitor previously approved to treat kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at 46th annual meeting of the American Society of Clinical Oncology in Chicago.

Sleep-disordered breathing is common but hard to detect in pediatric patients
An estimated 18 percent of pediatric patients in a University of North Carolina-based study were at-risk for sleep-related breathing disorders.

Targeted intraoperative radiotherapy is as good as whole breast radiotherapy at reducing breast cancer recurrence, and can be carried out in one hospital visit (TARGIT-A trial)
Targeted intraoperative radiotherapy for breast cancer -- in which radiotherapy is confined to the area of the breast where the tumour has been removed -- is as good as whole breast radiotherapy at reducing breast cancer recurrence, and can be carried out in one hospital visit.

Second-line CML drugs evoke faster, better front-line remissions
Separate international phase III clinical trials compared high-quality remissions between previously untreated CML patients who took the standard-of-care drug imatinib and those on the second-generation drugs dasatinib and nilotinib.

Questionnaires help dentists screen for sleep-disordered breathing in children
According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, questionnaires can help dentists screen for sleep-disordered breathing in a pediatric population.

Tongue measurements may help dentists determine oral appliance therapy success for sleep apnea
According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the ratio between tongue volume and bony enclosure size in patients with obstructive sleep apnea may help dentists calculate oral appliance treatment success.

Desperate female spiders fight by different rules
In most animals the bigger, better fighter usually wins. But a new study of the jumping spider Phidippus clarus suggests that size and skill aren't everything -- what matters for Phidippus females is how badly they want to win.

Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at the University of Texas MD Anderson Cancer Center.

Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.